Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.31 |
| ▸ | FEN1 | P39748 | 7/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276618 | 0.88 | KDM4E (0.35) | APPALOX5APFEN1 | |
| SCHEMBL10275748 | 0.88 | APP (0.35) | PDE3BPDE3AAPPDHODHHTR2A | |
| SCHEMBL10275359 | 0.87 | PDE3B (0.36) | PDE3BPDE3ADHODHHTR2AGRM2 | |
| SCHEMBL10276613 | 0.84 | PDE3B (0.32) | PDE3BPDE3ADYRK1AKLKB1DHODH | |
| SCHEMBL10276615 | 0.84 | PDE3B (0.32) | PDE3BPDE3ADYRK1AKLKB1DHODH | |
| SCHEMBL10313539 | 0.84 | MEN1 (0.33) | PDE3BPDE3ADHODHHTR2AGRM2 | |
| SCHEMBL10276050 | 0.81 | MEN1 (0.35) | ALOX5APFEN1 | |
| SCHEMBL10276329 | 0.80 | PDE3B (0.34) | PDE3BPDE3AAPPBACE1ALOX5AP | |
| SCHEMBL10275668 | 0.76 | ALOX5AP (0.35) | PDE3BPDE3AAPPHTR2AGRM2 | |
| SCHEMBL10275729 | 0.76 | KDM1A (0.37) | PDE3BPDE3AHTR2AGRM2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011035518-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | 辽宁利锋科技开发有限公司 (CN) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PDE3B 2361/4885PDE3A 2182/4885DYRK1A 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.